# Prevalence of chronic viral hepatitis B, D among Mongol migrants in Sweden compared to a sex- and age-matched native Mongol cohort

**Authors:** Delgersaikhan Zulkhuu, Habiba Kamal, Sanjaasuren Enkhtaivan, Ochirmaa Narantsogt, Ganbolor Jargalsaikhan, Munguntsetseg Batkhuu, Byambasuren Ochirsum, Marcus Ahl, Karin Lindahl, Michael Ingre, Natalie Stiglund, Alexandros Petropoulos, Gustaf Sandh, Niklas K. Björkström, Sonja Saario, Susanne Cederberg, Annika Olsson, Anna Wange Baye, Ihssan Derdabi, Desideria Georgos, Andreas S. Bungert, Nara Bungert Dashdorj, N. D. Dashdorj Onom, Soo Aleman

PMC · DOI: 10.1186/s12879-025-12506-w · BMC Infectious Diseases · 2026-01-16

## TL;DR

This study found that Mongol migrants in Sweden have lower rates of chronic hepatitis B and D compared to native Mongols but higher than the general Swedish population, highlighting the need for better screening and care.

## Contribution

The study provides new prevalence data for chronic hepatitis B and D among Mongol migrants in Sweden and compares it with a matched native Mongol cohort.

## Key findings

- HBsAg+ prevalence was 4.4% among Mongol migrants in Sweden, lower than 9.8% in native Mongols.
- Only 6.8% of those with chronic hepatitis were linked to care, indicating a gap in diagnosis and treatment.
- Anti-HCV+ prevalence was 18.6%, with 13.3% having detectable HCV-RNA, showing chronic infection.

## Abstract

Chronic hepatitis B/D is the most severe form of chronic viral hepatitis, yet public awareness of its burden remains low. This study examined the prevalence of viral hepatitis B and D among Mongol migrants in Sweden and facilitated linkage to care.

We conducted a viral hepatitis screening event on January 28th -29th, 2023 at Karolinska University Hospital, Stockholm, for individuals of Mongol descent. Consenting participants underwent blood testing and liver stiffness measurements. The prevalence of viral hepatitis was compared with an age- and sex-matched general population cohort in Mongolia.

We screened 850 adult Mongols (mean age (SD) 43.2 ± 8.6 years; 61.9% women). The prevalence of HBsAg+, anti-HDV+, and HDV-RNA + were 4.4%, 2.1%, and 1.3%, respectively. The corresponding prevalences in the matched native Mongol cohort were significantly higher at 9.8%, 5.1%, and 3.7%. Among HBsAg + individuals, 48.6% were anti-HDV+; 61.1% of anti-HDV + individuals had detectable HDV-RNA. Prior HBV infection was identified in 62.9% of participants, 8.7% had evidence of vaccination, and 22.8% were susceptible to HBV infection. Overall, 58 (6.8%) individuals with chronic viral hepatitis were linked to care. Among HBsAg + or anti-HBc + individuals, only 54.1% and 65.8% were aware of their current or past HBV infection, respectively. Anti-HCV + prevalence was 18.6%; 13.3% had detectable HCV-RNA, indicating chronic infection.

Mongol migrants had lower prevalences of hepatitis B and D than the general population in Mongolia, but higher than in the Swedish general population. Increased screening efforts are needed to enhance awareness, improve diagnosis and linkage to care for populations at higher risk of chronic viral hepatitis in Sweden and Europe.

The online version contains supplementary material available at 10.1186/s12879-025-12506-w.

## Linked entities

- **Diseases:** hepatitis B (MONDO:0005344), hepatitis D (MONDO:0005789)

## Full-text entities

- **Genes:** KRT88P (keratin 88, pseudogene) [NCBI Gene 85348] {aka HBC, KRT122P, KRTHBP3}
- **Diseases:** PIN (MESH:D003638), CAP (MESH:C538265), HBV and HCV infection (MESH:D006525), morbidities (OMIM:614963), viral hepatitis (MESH:D014777), HDV (MESH:D003699), hepatitis (MESH:D056486), overweight (MESH:D050177), liver disease (MESH:D008107), Chronic hepatitis D virus ( (MESH:D019701), metabolic (MESH:D008659), steatosis (MESH:D005234), Infection (MESH:D007239), chronic infection (MESH:D000088562), obese (MESH:D009765), Chronic hepatitis B/D (MESH:D019694), HCV (MESH:D006526), LS (MESH:D017093), chronic hepatitis C (MESH:D019698), cirrhosis (MESH:D005355), Infectious Diseases (MESH:D003141), HCC (MESH:D006528), end-stage liver disease (MESH:D058625), HBV infection (MESH:D006509), advanced (MESH:D020178), stiffness (MESH:C566112), liver fibrosis (MESH:D008103), tuberculosis (MESH:D014376)
- **Chemicals:** Bulevirtide (MESH:C000718249), alcohol (MESH:D000438), lipid (MESH:D008055), anti (-), Tenofovir (MESH:D000068698)
- **Species:** Hepatitis B virus (no rank) [taxon 10407], Homo sapiens (human, species) [taxon 9606], hepatitis C [taxon 11103], Hepatitis delta virus (no rank) [taxon 12475], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12849161/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12849161/full.md

## References

8 references — full list in the complete paper: https://tomesphere.com/paper/PMC12849161/full.md

---
Source: https://tomesphere.com/paper/PMC12849161